Biologics Contract Development Global Market Report 2024

The global biologics contract development market has grown rapidly in recent years. It will grow from $6.94 billion in 2023 to $7.7 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth observed in the historical period can be attributed to various factors. Firstly, it is linked to the overall growth of the biologics market, which experienced expansion during this period. The rise in biopharmaceuticals, characterized by the development and utilization of biological products in the pharmaceutical industry, played a significant role. The inherent complexity of biologics, both in terms of development and manufacturing, contributed to the demand for specialized contract development services. Patent expirations in the industry also drove companies to explore cost-efficient outsourcing options, leading to increased reliance on biologics contract development services.

The global biologics contract development market is expected to see rapid growth in the next few years. It will grow to $11.68 billion in 2028 at a compound annual growth rate (CAGR) of 11.0%. Anticipated growth in the forecast period is driven by key factors such as the integration of digitalization and data analytics, effective risk management practices, the flexibility and scalability offered by contract development services, a substantial increase in research and development (R&D) investments, and the growing focus on precision medicine and personalized therapies. Major trends expected in this period include the prominence of regenerative medicine, a continued emphasis on robust risk mitigation strategies, a rise in global collaborations, the adoption of advanced technologies, and a significant focus on technological integration within the industry. These trends reflect the dynamic landscape of the contract development sector and the ongoing pursuit of innovative and efficient business practices.

The biologics contract development market is poised for growth due to the increasing prevalence of chronic diseases, necessitating ongoing medical attention and novel drug development. The World Health Organization reported in April 2021 that approximately 71% of global deaths, totaling 41 million people annually, are attributed to chronic diseases. This surge in chronic conditions fuels the demand for biologics, positioning the biologics contract development market for substantial expansion.

A significant upswing in investments in biopharmaceuticals is a key driver of the biologics contract development market. The heightened demand for biopharmaceuticals, encompassing monoclonal antibodies, recombinant proteins, and gene therapies, prompts companies to outsource development activities. In January 2021, FUJIFILM Corporation invested $2 billion to establish a large-scale cell culture production site in the United States, accelerating its biopharmaceutical contract development and manufacturing business. This influx of investment is set to play a pivotal role in propelling the biologics contract development market.

Technological advancements are reshaping the biologics contract development market, with major players incorporating advanced technologies to maintain their market standing. In January 2022, Lonza introduced the bYlok technology platform, designed to facilitate the design and manufacture of bispecific antibodies. This platform addresses challenges related to light-heavy chain mispairing, ensuring high yields, accuracy exceeding 95%, and compatibility with a monoclonal antibody (mAb)-like format. Technological innovation remains a focal point in sustaining competitiveness within the biologics contract development sector.

Major companies operating in the biologics contract development arena are integrating data analytics into their processes, fostering improved monitoring, analysis, and decision-making. This integration of digital technologies enhances efficiency and productivity in biologics development. In October 2022, Evotec SE launched PanHunter, part of the PanOmics data access and analytics technology, which enables advanced patient population stratification and prediction of efficacy and toxicity profiles. This incorporation of data analytics signifies a strategic move towards leveraging digital tools for enhanced insights in the biologics contract development market.

Strategic acquisitions play a pivotal role in reinforcing companies' positions in the biologics contract development market. In February 2022, Recipharm acquired Vibalogics and Arranta Bio, strengthening its presence in advanced therapy medicinal products and expanding virotherapy manufacturing capabilities in the US. Vibalogics and Arranta Bio, both contract development and manufacturing organizations, were pivotal acquisitions contributing to Recipharm's strategic growth in the biologics contract development sector.

Major companies operating in the biologics contract development market report are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc., LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., AbbVie Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Meridian Life Science Inc., Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Sartorius AG, Syngene International Limited, Vibalogics GmbH, Yposkesi, and ZymoGenetics Inc.

North America was the largest region in the biologics contract development market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics contract development market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary sources for biologics contract development include microbial, mammalian, and other sources. Microbial sources are utilized in the production of various biologics. Biologics contract development caters to various indications, including oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others. The product services offered in biologics contract development encompass cell line development, process development, and other related services.

This report provides biologics contract development market statistics, including biologics contract development industry global market size, regional shares, competitors with a biologics contract development market share, detailed biologics contract development market segments, market trends and opportunities, and any further data you may need to thrive in the biologics contract development industry. This biologics contract development market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biologics contract development market includes revenues earned by entities by sourcing, solid and specialized formulation development, and process analytics development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.